# Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

> **NCT05254847** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 65 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Capecitabine combined with lenvatinib and tislelizumab

## Key facts

- **NCT ID:** NCT05254847
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2023-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05254847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05254847, "Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05254847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*